Principal Financial Group Inc Bei Gene, Ltd. Transaction History

Principal Financial Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$221.31 - $316.61 $937,911 - $1.34 Million	-4,238 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$189.18 - $286.44 $48,430 - $73,328	-256 Reduced 5.7%	4,238 $1.21 Million
Q2 2020 Aug 05, 2020	BUY	$123.9 - $195.41 $176,185 - $277,873	1,422 Added 46.29%	4,494 $846,000
Q1 2020 May 12, 2020	BUY	$121.84 - $173.19 $30,094 - $42,777	247 Added 8.74%	3,072 $378,000
Q4 2019 Feb 05, 2020	SELL	$115.78 - $208.34 $5,210 - $9,375	-45 Reduced 1.57%	2,825 $468,000
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $12,302 - $15,125	102 Added 3.68%	2,870 $351,000
Q2 2019 Aug 12, 2019	BUY	$113.99 - $146.86 $29,979 - $38,624	263 Added 10.5%	2,768 $343,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $268,060 - $438,750	2,505 New	2,505 $351,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.